08:00 , Mar 4, 2002 |  BC Week In Review  |  Company News

Access Pharmaceuticals, Biotech Australia Pty Ltd. deal

AKC acquired Biotech Australia's targeted therapeutics division, including cancer IP and a scientific research group, for an undisclosed sum of cash and stock payable over three years. The IP covers folate conjugates of polymer therapeutics...
08:00 , Dec 4, 2000 |  BC Week In Review  |  Company News

CropDesign, Grain Biotech Australia Pty Ltd. deal

The companies formed a joint wheat development alliance to introduce CropDesign's yield enhancement technologies into commercial wheat varieties. The alliance has exclusive rights to the program for Australia, and CropDesign has exclusive rights elsewhere. CropDesign...
07:00 , Aug 31, 1998 |  BC Week In Review  |  Clinical News

Plasminogen activator inhibitor 2: Phase I data; Phase II

Biotech Australia said that Phase I safety testing of its inhibitor of tissue degradation showed a 25 percent average reduction in the size of ulcers at 28 days post-treatment. Patients in the trial received daily...
07:00 , Jun 7, 1993 |  BC Week In Review  |  Company News

Cistron deal

Cistron Biotechnology Inc. (CIST)   Cistron Biotechnology Inc. (CIST) granted Biotech Australia Pty. Ltd. an exclusive U.S. license for a DNA patent to make, use and sell plasminogen activator inhibitor. Financial terms weren't disclosed. Biotech...